Effect of Chlamydia pneumoniae infection and hyperlipidaemia on the expression of PPARγ, P50 and c-Fos in aortic endothelial cells in C57BL/6J mice

Acta Cardiologica

Volumn 60, Issue 1, 2005, Pages 43-49

  Huang, Bingsheng ^a   Dong, Yugang ^a   Mai, Weiyi ^a   Li, Yongqiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

AP 1; Chlamydia pneumoniae; Endothelium; Hypercholesterolaemia; NF B; PPAR

Indexed keywords

CHOLESTEROL; CHOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN C FOS; PROTEIN P50; SCARLET RED; TRANSCRIPTION FACTOR AP 1; AUTACOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; AORTA SINUS; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; METABOLISM; NEEDLE BIOPSY; ONCOGENE; PATHOLOGY; PROBABILITY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM;

ANIMALS; BIOPSY, NEEDLE; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GENES, FOS; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; NF-KAPPA B; PPAR GAMMA; PROBABILITY; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTOR AP-1;

EID: 17944366037     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.60.1.2005048     Document Type: Article

References (32)

1. Saikkn P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
2. Saikkn P, Leinoner M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Manttari M, Frick MH. Chronic Chlamydia pneumoniae infection as risk factor for coronary heart disease in the Helsinki Heart study. Ann Intern Med 1992; 116: 273-8.
3. Linnanmaki E, Leinonen M, Mattila K, Nieminan MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 4: 1130-4.
4. Blessing E, Campbell LA, Rosenfeld ME, Chough N, Kuo CC. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 2001; 158: 13-7.
5. Blessing E, Campbell LA, Rosenfeld ME, Kuo CC. Chlamydia preumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Infect Immun 2002, 70: 5332-4.
6. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 1999, 340 (2): 115-25.
7. Mano H, Kimura C, Fujisawa Y, Kameda T, Watanabe-Mano M, Kaneko H, Kaneda T, Hakeda Y, Kumegawa M. Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts. J Biol Chem 2000, 11: 8126-32.
8. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987, 68: 231-40.
9. Renier G, Skamene E, DeSanctis J, Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities. Arterioscl Thromb 1993; 13 (10): 1515-24.
10. Liu YF, ed. Immunofluorescence. Chemistry in Immunohistology. Publication of People's Health in Beijing, 1989, 47-143 (in Chinese).
11. Clark RB, Bishop-Bailey D, Estrada-Hernandez C, Hla T, Puddington L, Padula ST. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 2000, 164 (3): 1364-71.
12. Tsubouchi Y, Sano H, Kawahit Y, Mukai S, Yamada R, Kohuo M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the PPARγ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270 (2): 400-5.
13. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347: 849-53.
14. Thieringer R, Fenyk-Melody JE, LeGrand CB. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000; 164: 1046-54.
15. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999; 274: 17042-8.
16. Wen YM, Lu DY, ed. Modern Medical Microbiology. Publication of Shanghai University of Medical Science, Shanghai, 1999, pp. 570-592 (In Chinese).
17. Longo WE, Damore LJ, Mazuski TE, Smith GS, Panesar N, Kaminski DL. The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation. Mediators Inflamm 1998, 7 (2): 85-91.
18. Casteleijn E, Kuiper J, Van Rooij HC, Kamps JA, Koster JF, Van Berkel TJ. Endotoxin stimulates glycogenolysis in the liver by means of intercellular communication. J Biol Chem 1988; 263: 6953-5.
19. 2 by murine macrophage cell lines. Protaglandins 1985, 30: 949-67.
20. Ginn-Pease ME, Whisler RL. Redox signals and NF-κB activation in T cells. Free Radic Biol Med 1998, 25: 346-61.
21. Epstein FH. NF-κB-a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997, 336: 11066-71.
22. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydiae pneumoniae activates NF-κB and AP-1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res 2000, 90: 76-81.
23. Wilson SH, Coplice NM, Simari RD, Holmes DR Jr, Carlsin PJ, Lerman A. Activated NF-κB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 2000, 148: 23-30.
24. Zhong L, You JL, Sun QB, Luo ZD. The effect of NF-κB in TNF alpha induced apoptosis of endothelium, National Medical Journal of China 1999, 79: 863-6 (in Chinese).
25. Angel P, Karin M. The role of Jun, Fos and the Ap-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57.
26. Webster KA, Discher DJ, Bishopric NH. Induction and nuclear accumulation of Fos and Jun proto-oncogenes in hypoxic cardiac myocytes. J Biol Chem 1993, 268: 16852-8.
27. Smeyne RJ, Vendrell M, Hayward M, Baker SJ, Miao GG, Schilling K, Robertson LM, Curran T, Morgan JI. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993; 363: 166-9.
28. Chen NG, Han X. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochem Biophys Res Commun 2001; 282: 717-22.
29. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activtor protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
30. Moazed T, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apo E-deficient mice. J Infect Dis 1999; 180: 238-41.
31. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999, 103: 747-53.
32. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.